Key result
Low-dose anthracycline chemotherapy did not significantly alter serum NT-proBNP levels (p=0.6) or left ventricular systolic and diastolic functions over a 9-month follow-up period.
Why the study?
The study aimed to evaluate the relationship between serum NT-proBNP levels and the incidence of LV systolic and diastolic dysfunction in patients receiving low-dose anthracycline chemotherapy.
Does low-dose anthracycline chemotherapy cause changes in serum NT-proBNP levels and left ventricular systolic and diastolic function in patients with cancer?
Observational (n=57)
Yes
Does low-dose anthracycline chemotherapy cause changes in serum NT-proBNP levels and left ventricular systolic and diastolic function in patients with cancer?
Low-dose anthracycline chemotherapy does not significantly alter serum NT-proBNP levels or left ventricular systolic and diastolic function over a 9-month follow-up in patients without prior cardiac disease.
Answers are grounded in this paper and cite their sources.
Supports short-term cardiac safety of low-dose anthracyclines; leaves open need for longer follow-up and randomized confirmation.
Background and Aims The present study aimed to evaluate the relationship between serum N‐terminal (NT)‐pro‐brain natriuretic peptide (BNP) levels and incidence of left ventricular (LV) systolic and diastolic dysfunction in patients who underwent low‐dose anthracycline chemotherapy. Methods This observational, prospective study was conducted on all patients with proven breast cancer, Hodgkin lymphoma, or non‐Hodgkin lymphoma and no history of previous cardiac or any chronic diseases who were candidates for low‐dose anthracycline chemotherapy from March 2017 to February 2018. We evaluated the serum NT‐proBNP level and performed trans‐thoracic echocardiography at baseline, 6, and 9 months after the chemotherapy. Results Among 57 patients who successfully finished the study, 13 (22.8%) patients were men and 44 (77.19%) patients were women, and the total mean age was 52 ± 14.86 years. Our results revealed that the LV systolic and diastolic function and NT‐proBNP mean levels were in the normal range at all three measured times. Additionally, no significant differences were observed between the levels of NT‐proBNP, LV systolic, and diastolic function at baseline, 6, and 9 months after chemotherapy with low‐dose anthracycline ( p = 0.6, 0.1, and 0.4, respectively). Conclusion Following low‐dose anthracycline chemotherapy, none of our patients encountered LV systolic and diastolic dysfunctions and changes in serum NT‐proBNP level. However, further studies with a larger population, longer follow‐up duration, and higher dosage of anthracyclines are required to determine the effects of low‐dose anthracycline on NT‐proBNP level and LV systolic and diastolic functions.
No takes yet. Share an insight, caveat, or question.
Mohammadi et al. (2022) conducted an observational in Breast cancer, Hodgkin lymphoma, or non-Hodgkin lymphoma (n=57). Low-dose anthracycline chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Serum NT-proBNP level (pg/ml) at 9 months (p=0.6). Low-dose anthracycline chemotherapy did not significantly alter serum NT-proBNP levels (p=0.6) or left ventricular systolic and diastolic functions over a 9-month follow-up period.
Synapse has enriched 10 related papers. Consider them for comparative context: